EYS-606 is under clinical development by Eyevensys and currently in Phase II for Posterior Uveitis. According to GlobalData, Phase II drugs for Posterior Uveitis have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EYS-606’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EYS-606 overview

EYS-606 is under development for the treatment of non-infectious posterior, intermediate uveitis (NIU), panuveitis and retinitis pigmentosa. EYS-606 administered through intraocular route. The drug candidate is a combination product and comprises of a DNA plasmid (nucleic acid) encoding a recombinant fusion protein TNF alpha p55 receptor, associated to a high precision electro-transfection-injection system (ETIS) which is linked to the human IgG1Fc domain.

Eyevensys overview

Eyevensys is a clinical-stage biotechnology company developing non-viral gene therapies. The company’s lead product EYS-809 is used for the treatment of wet age-related macular degeneration (AMD) and geographic atrophy and its EYS611 program is used against the treatment of geographic atrophy and retinitis pigmentosa. It also offers the EYS-606 program for the treatment of chronic non-infectious uveitis. The company works in partnership with organizations such as boehringer ingelheim, bpifrance and apdecisif among others. Eyevensys is headquartered in Paris, France.

For a complete picture of EYS-606’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.